PLK1 and non-small cell lung carcinoma: The results confirmed that FOXM1 activity was reduced by depletion of PLK1 and increased upon cisplatin treatment, accompanied by the increase of CCNB1, ultimately resulting in cell cycle arrest in NSCLC cells with PLK1 deficit.